TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15347608

Group type: EXPERIMENTAL
Intervention: Hyperbaric ropivacaine 10 mg/ml (1.5 ml) with glucose 300 mg/ml (0.5 ml)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Plain ropivacaine 7.5 mg/ml (2 ml)
Number of subjects: 56
Study: 11291821

Group type: EXPERIMENTAL
Intervention: Twisting task with a moment of 20 Nm for 20 min at 10 repetitions min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lateral bend task with a moment of 20 Nm for 20 min at 10 repetitions min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flexion task with a moment of 20 Nm for 20 min at 10 repetitions min(‐1)
Number of subjects: 20
Study: 9869959

Group type: EXPERIMENTAL
Intervention: High-frequency pacing (HFP) at 50 Hz, 10 mA, applied at the high right atrium with burst durations of 500, 1000, 2000, and 4000 ms.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-frequency pacing (HFP) at 50 Hz, 10 mA, applied at the high right atrium.
Number of subjects: 22
Study: 8323840

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3548803

Group type: EXPERIMENTAL
Intervention: Treatment group (AD and estimated weight reported)
Number of subjects: 2771

Group type: COMPARATOR
Intervention: Control group (AD and estimated weight withheld)
Number of subjects: 2771
Study: 31402538

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5 mg, 10 mg, or 25 mg once daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 27658659

Group type: EXPERIMENTAL
Intervention: Antioxidant ice cream (100 g containing dark cocoa powder, hazelnut, and green tea extracts)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Milk chocolate ice cream (control ice cream)
Number of subjects: 14
Study: 25713428

Group type: EXPERIMENTAL
Intervention: gemcitabine-docetaxel plus bevacizumab
Number of subjects: 107

Group type: COMPARATOR
Intervention: gemcitabine-docetaxel plus placebo
Number of subjects: 107
Study: 23597082

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and problem solving treatment (n=314)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Health brochures (Control group, n=308)
Number of subjects: 622
Study: 21568075

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg t.i.d.)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ ibuprofen
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide +/‐ piroxicam
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ piroxicam
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (hypertensives with no osteoarthritis)
Number of subjects: 110
Study: 19159477

Group type: EXPERIMENTAL
Intervention: Emergency Clinical Pathway (ECP) trained EMS and ER health professionals
Number of subjects: 4895

Group type: COMPARATOR
Intervention: Non-trained EMS and ER controls
Number of subjects: 4895
Study: 16387395

Group type: EXPERIMENTAL
Intervention: Proficiency training in patient transfer methods (one transfer before and one after training)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No proficiency training (two transfers before training)
Number of subjects: 71
Study: 15190995

Group type: EXPERIMENTAL
Intervention: Specific reminiscence program (life-story approach)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Friendly discussions (comparison group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 101
Study: 11071672

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy (cisplatin 60 mg/m² on day 1, etoposide 120 mg/m² on days 1-3, concurrent with radiotherapy 50.4 Gy in 28 fractions)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Radiotherapy alone (50.4 Gy in 28 fractions)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy
Number of subjects: 488

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 488
Study: 8851570

Group type: EXPERIMENTAL
Intervention: 1,000 mg twice daily with food
Number of subjects: 6

Group type: COMPARATOR
Intervention: 1,000 mg once daily with food
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1,000 mg twice daily fasting
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1,500 mg single dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1,000 mg single dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1,000 mg twice daily with high-fat meal
Number of subjects: 6
Study: 1315665

Group type: EXPERIMENTAL
Intervention: Drug therapy plus plasmapheresis (plasma exchange)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard drug therapy alone
Number of subjects: 86
Study: 6385935

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31780586

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 29903344

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT) - aspirin 325 mg and clopidogrel 75 mg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Lower intensity warfarin plus aspirin (INR 1.5 to 2.0)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Standard warfarin plus aspirin (INR 2.0 to 3.0)
Number of subjects: 576
Study: 26701371

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PTZ)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (IMP)
Number of subjects: 105
Study: 24939671

Group type: EXPERIMENTAL
Intervention: Baseline uric acid (UA) levels
Number of subjects: 131
Study: 22513699

Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 2506
Study: 20580349

Group type: EXPERIMENTAL
Intervention: Sitz baths with water at a temperature of less than 15 degrees C
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sitz baths with water temperature above 30 degrees C
Number of subjects: 24
Study: 17628650

Group type: EXPERIMENTAL
Intervention: Counselor-initiated, individually tailored telephone counseling smoking cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study: 16153204

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-induced fluorescence cystoscopy (FC) during transurethral resection (TUR)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard white-light endoscopy during transurethral resection (TUR)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-induced fluorescence cystoscopy (FC) during TUR
Number of subjects: 122
Study: 12371711

Group type: EXPERIMENTAL
Intervention: 12-hour group education on healthy lifestyle
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 10422531

Group type: EXPERIMENTAL
Intervention: 1 presentation of automated appointment messages
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2 presentations of automated appointment messages
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 3 presentations of automated appointment messages
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Additional retrieval support with repetition
Number of subjects: 2
Study: 8526179

Group type: EXPERIMENTAL
Intervention: Immunotherapy with specific hyposensitization (Abelló Lab., Spain) for 12 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1483486

Group type: EXPERIMENTAL
Intervention: S-1452 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6529162

Group type: EXPERIMENTAL
Intervention: Alizapride (50 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 21
Study: 31298721

Group type: EXPERIMENTAL
Intervention: RayOne Trifocal
Number of subjects: 30

Group type: COMPARATOR
Intervention: FineVision POD F
Number of subjects: 30
Study: 29396080

Group type: EXPERIMENTAL
Intervention: Embedded behavioral clinician (BC) delivering SBIRT
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Pediatrician-only delivering SBIRT
Number of subjects: 648

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 648
Study: 27006237

Group type: EXPERIMENTAL
Intervention: HT-enriched biscuits (HT-B)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-enriched biscuits (C-B)
Number of subjects: 13
Study: 23895403

Group type: EXPERIMENTAL
Intervention: WDYD intervention (web-based brief alcohol intervention)
Number of subjects: 609

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 609
Study: 21865319

Group type: EXPERIMENTAL
Intervention: Silymarin (280 or 560 mg) every 8 hours for 7 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19295301

Group type: EXPERIMENTAL
Intervention: New therapeutic interventions for heart rate control and increased pumping ability of the heart; specific interventions not detailed.
Number of subjects: 0
Study: 17115269

Group type: EXPERIMENTAL
Intervention: Educational course (n = 80)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Brochure with correct answers (n = 81)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No intervention (n = 79)
Number of subjects: 240
Study: 15669550

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study: 11728684

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT) at a dosage of 46 Gy
Number of subjects: 715

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 715
Study: 9106379

Group type: EXPERIMENTAL
Intervention: 75 mg diphenhydramine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 30
Study: 1494218

Group type: EXPERIMENTAL
Intervention: I system connector (n = 106)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Luer‐Lock connector (n = 124)
Number of subjects: 230
Study: 3885674

Group type: EXPERIMENTAL
Intervention: Netilmicin and ticarcillin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tobramycin and ticarcillin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 17
Study: 31170104

Group type: EXPERIMENTAL
Intervention: Riboflavin (0.1%) + hydroxylpropyl methylcellulose instillation without eyelid speculum (group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Riboflavin (0.1%) + hydroxylpropyl methylcellulose instillation with eyelid speculum (group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 48
Study: 28671879

Group type: EXPERIMENTAL
Intervention: Protective ventilation (Vt 7 mL/kg-PEEP 5 mm Hg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional ventilation (Vt 9 mL/kg-PEEP 0 mm Hg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Protective ventilation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional ventilation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both ventilation modes
Number of subjects: 32
Study: 27112612

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BIV)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVA)
Number of subjects: 118
Study: 23903901

Group type: EXPERIMENTAL
Intervention: Intrathecal normal saline 5 ml before intrathecal injection of 2.5 ml (12.5 mg) hyperbaric bupivacaine 0.5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received 2.5 ml (12.5 mg) hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study: 22652586

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Maternal allergy
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: High OVA IgA antibodies in colostrum
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Low levels of OVA IgA in mature breast milk
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: TGF-β(2) levels in breast milk
Number of subjects: 364
Study: 20736446

Group type: EXPERIMENTAL
Intervention: Hypothermia (cold saline infusion and endovascular cooling)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 20
Study: 18418793

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion SR + Counseling
Number of subjects: 0
Study: 15845775

Group type: COMPARATOR
Intervention: Anti-G suit inflated to 85 mmHg at 1 G
Number of subjects: 12

Group type: COMPARATOR
Intervention: Anti-G suit inflated to 85 mmHg at 2 G
Number of subjects: 12
Study: 12409170

Group type: EXPERIMENTAL
Intervention: 12-week stress management program with follow-up sessions
Number of subjects: 121

Group type: COMPARATOR
Intervention: Participation in a social activities group
Number of subjects: 121
Study: 10047926

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine hydrochloride (APO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Optimal doses of carbidopa/levodopa
Number of subjects: 10
Study: 7734309

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 436

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Pathological factors (tumour size, macroscopic type, number of sites involved, depth of invasion, involvement of resection lines, lymph nodes, histological grade)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Lauren classification and histological grade
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Lymphocytic and eosinophilic infiltration, presence of dysplasia
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Depth of invasion, resection line, nodal involvement
Number of subjects: 436
Study: 2251632

Group type: EXPERIMENTAL
Intervention: Synthetic laminaria tent (Lamicel; Cabot)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2) oral tablets used intravaginally
Number of subjects: 80
Study: 94638

Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29581037

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30)
Number of subjects: 15357

Group type: COMPARATOR
Intervention: Overweight patients (BMI 25-29.99)
Number of subjects: 15357

Group type: COMPARATOR
Intervention: Normal weight patients (BMI 18.5-24.99)
Number of subjects: 15357
Study: 28153005

Group type: EXPERIMENTAL
Intervention: AbMIP
Number of subjects: 25
Study: 26616798

Group type: EXPERIMENTAL
Intervention: APC with medicine group (Esomeprazole 40 mg/d after APC treatment for 8 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: APC with surgery group (Laparoscopic hiatal hernia repair and Nissen fundoplication after APC treatment)
Number of subjects: 61
Study: 24114152

Group type: EXPERIMENTAL
Intervention: Preschool Life Skills Program (PLS); teaching strategies included instruction, modeling, role play, and differential reinforcement.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no PLS program); participated in small-group activities without the intervention.
Number of subjects: 12
Study: 21860294

Group type: EXPERIMENTAL
Intervention: Retrograde voiding trial
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spontaneous voiding trial
Number of subjects: 50
Study: 19820283

Group type: EXPERIMENTAL
Intervention: P-OM3 4 g/day + fenofibrate 130 mg/day
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (4 g/day corn oil) + fenofibrate 130 mg/day
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Non-switchers (P-OM3 + fenofibrate) during extension phase
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Switchers (P-OM3 + fenofibrate) during extension phase
Number of subjects: 167
Study: 17955091

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) such as gabapentin and pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15110372

Group type: EXPERIMENTAL
Intervention: Prone View (PV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prone Positioner (PP)
Number of subjects: 35
Study: 11298069

Group type: EXPERIMENTAL
Intervention: 500 mg of racemic halofantrine once daily in the fasted state for 42 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9580646

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study: 7905904

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 240
Study: 2647907

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine (less than 30 mg/day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Low-dose levodopa-carbidopa (less than 600/150 mg/day)
Number of subjects: 129
Study: 30987594

Group type: EXPERIMENTAL
Intervention: Premedication with flunitrazepam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prewarming using an underbody forced-air warming blanket
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no prewarming)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prewarming
Number of subjects: 50
Study: 28466507

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 60
Study: 26228333

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (Group A)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Conventional mesh repair (Group B)
Number of subjects: 337
Study: 23138693

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 20
Study: 20568433

Group type: EXPERIMENTAL
Intervention: Herb-partitioned spread moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Sulfasalazine
Number of subjects: 60
Study: 18173345

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Microscopic discectomy (MD)
Number of subjects: 15
Study: 16891998

Group type: EXPERIMENTAL
Intervention: Moclobemide and supportive guidance
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) and pill placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combination of moclobemide and group cognitive-behavioral therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (pill placebo)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CBT (during 24-month follow up)
Number of subjects: 81
Study: 14691773

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparisons between CAS and CEA
Number of subjects: 0
Study: 10899408

Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8676185

Group type: EXPERIMENTAL
Intervention: Continuing education seminars (3 seminars over 4 months)
Number of subjects: 5685
Study: 2049967

Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFX) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination treatment with Ofloxacin (OFX) and a single dose of aminoglycoside (isepamicin)
Number of subjects: 0
Study: 6128447

Group type: EXPERIMENTAL
Intervention: Food intolerance challenge (double blind)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Challenge foods
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Food intolerance
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rectal PGE2
Number of subjects: 21
Study: 31663671

Group type: EXPERIMENTAL
Intervention: Elective course on preliminary structural biology, duration 15 weeks, involving cloning, expression, purification, and crystal screening of HpaA.
Number of subjects: 18
Study: 31575591

Group type: EXPERIMENTAL
Intervention: Thirst intervention performed by nurses
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Thirst intervention performed by family members
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nurse and family member burden levels
Number of subjects: 136
Study: 28662152

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study: 26425078

Group type: EXPERIMENTAL
Intervention: 40% experimental load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 80% experimental load
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 23438803

Group type: EXPERIMENTAL
Intervention: 20 mL 2% articaine (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mL 2% articaine + 10 mL 0.75% ropivacaine (Group AR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20 mL 0.75% ropivacaine (Group R)
Number of subjects: 60
Study: 21543543

Group type: EXPERIMENTAL
Intervention: Early nutrition program with varying diets during the neonatal period (no phosphate supplements provided)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher proportion of unsupplemented human milk in the neonatal diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preterm subjects compared to population reference data
Number of subjects: 20
Study: 19375574

Group type: EXPERIMENTAL
Intervention: Urinary Distress Inventory (UDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UDI‐stress subscale of the Pelvic Floor Distress Inventory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary Impact Questionnaire (UIQ)
Number of subjects: 0